

Precision Nanomedicine in Cardiothoracic Oncology: Overcoming the Clinical Paradox of Cisplatin through Supramolecular and Stimuli-Responsive Engineering

Panijapatr Wasubhadtanasaka

Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, 56000, TH


Submitted: March 26, 2026

Accepted: April 18, 2026

Published: May 12, 2026

Graphical Abstract

Real-Time Theranostics: Integrating Nano-Platforms into Surgical Decision-Making



Abstract

Cisplatin remains a foundational standard for treating solid thoracic malignancies, particularly non-small cell lung cancer (NSCLC). However, its clinical utility is continually constrained by a profound “clinical paradox” in which exceptional cytotoxic potency is offset by a dangerously narrow therapeutic index. From a cardiothoracic surgical perspective, dose-limiting nephrotoxicity represents a direct obstacle that may prematurely close the “optimal surgical window” by depleting a patient’s physiological reserve. This review evaluates advanced drug delivery systems (DDS)—specifically cyclodextrin-complexed liposomes and stimuli-responsive nanovesicles—as essential tools for navigating biological bottlenecks, such as intracellular thiol sequestration and transport downregulation. Molecular engineering strategies, including sheddable polyethylene glycol (PEG) shields and zwitterionic coatings, are examined for their potential to bypass accelerated blood clearance (ABC) and immune recognition. Furthermore, the integration of green nanotechnology and theranostic imaging for real-time intraoperative monitoring is highlighted, enabling clinicians to titrate fluid management and vasopressor support with enhanced precision. By utilizing precision platforms such as NC-6004 (Nanoplatin), which achieves a maximum tolerated dose of 135 mg/m²—nearly double the standard regimen—with superior tolerability, clinicians can facilitate “surgical reclaimability” for previously unfit patients. Ultimately, these nanomedicines decouple systemic toxicity from oncological efficacy, ensuring patients maintain the physiological integrity necessary for survival during high-stakes thoracic procedures.

Keywords: Cisplatin, Cardiothoracic Surgery, Cyclodextrin, Nephrotoxicity, Nanomedicine, Surgical Window, Stimuli-Responsive, Surgical Reclaimability.

Rationale, Purpose, and Limitations

Cisplatin remains a foundational treatment for solid thoracic malignancies, yet its narrow therapeutic index creates a "clinical paradox" where exceptional potency is offset by severe nephrotoxicity. For cardiothoracic surgeons, this toxicity often depletes a patient's physiological reserve, prematurely closing the optimal surgical window and rendering technically resectable tumors unviable.

This paper aims to evaluate how advanced supramolecular and stimuli-responsive nanomedicines can resolve this paradox by decoupling systemic toxicity from oncological efficacy. By using precision platforms such as NC-6004, this review demonstrates how clinicians can facilitate "surgical reclaimability," enabling previously unfit patients to safely undergo curative resection.

Despite promising clinical benchmarks, significant hurdles remain in manufacturing reproducibility at an industrial scale and navigating the complex regulatory landscape for multi-component nanohybrids. Furthermore, biological phenomena such as accelerated blood clearance (ABC) and high interstitial pressure in solid tumors continue to challenge the deep penetration and long-term efficacy of these advanced delivery systems.

Introduction

The Clinical Paradox of Platinum-Based Therapy

Cisplatin remains a cornerstone of systemic therapy for solid malignancies, specifically NSCLC. Despite the emergence of immunotherapy and targeted molecular agents, platinum-based regimens remain the standard of care for both primary and adjuvant treatment.¹ However, the clinical utility of cisplatin is characterized by a profound paradox: while the agent is exceptionally potent in inducing DNA cross-linking and subsequent apoptosis in malignant cells, its therapeutic index is notoriously narrow.^{2,3}

The Surgical Oncology Perspective

From the perspective of a cardiothoracic (CVT) surgeon, the systemic toxicity of cisplatin is not merely a side effect; it is a direct obstacle to surgical success. High-dose cisplatin often leads to nephrotoxicity, which can cause a rapid decline in renal function, precluding the patient from reaching an optimal surgical window.³ If a patient's physiological reserve is depleted by the "first-hit" of chemotherapy, the risks of perioperative complications increase significantly.⁴ Therefore, the engineering of advanced DDS is a surgical necessity, ensuring that patients remain candidates for resection while receiving maximal therapeutic doses.⁴




Figure 1: Surgical reclaimability: restoring the path to curative resection.

The challenge of intracellular thiol sequestration is more than a biochemical nuisance—it is a physiological barrier that dictates the feasibility of a resection. When glutathione (GSH) levels rise in thoracic malignancies such as NSCLC or esophageal carcinoma, the resulting drug resistance often drives a shift toward higher systemic cisplatin doses to achieve a therapeutic response.

This escalation creates a “vicious cycle” that directly impacts the perioperative period and the patient’s long-term surgical viability.

In cardiothoracic (CVT) surgery, the patient’s physiological reserve is a critical determinant of survival.⁵ High-dose cisplatin administration, often necessitated by thiol-mediated resistance in tumor cells, frequently results in subclinical or overt nephrotoxicity due to the drug’s accumulation in proximal tubular cells of the kidney.^{6,8}

Renal-Cardiac Feedback and Fluid Management

A decline in renal function, marked by a reduction in glomerular filtration rate (GFR), significantly complicates fluid management during major procedures.¹⁰ For patients undergoing cardiopulmonary bypass or major thoracic shifts, impaired renal excretion increases the risk of fluid overload and electrolyte imbalances.¹² These complications are especially dangerous in patients undergoing high-stakes procedures like pneumonectomy or lobectomy, where the risk of cardiovascular strain and pulmonary edema is heightened.^{9,11}

The Surgical Window

The “optimal surgical window” (Figure 1) refers to the period where a patient is fit enough to withstand the physiological stress of surgery while their disease remains resectable.¹³ When cisplatin-induced nephrotoxicity leads to a significant reduction in creatinine clearance, this window may close.⁷ In such cases, despite a tumor being technically resectable, the patient’s compromised renal state may leave them unable to endure the hemodynamic fluctuations inherent in major thoracic surgery.¹⁰

Molecular Bottlenecks and the Mechanisms of Platinum Resistance

The clinical utility of cisplatin in treating solid tumors is frequently compromised by the emergence of acquired resistance, a phenomenon

driven by a complex, multifactorial suite of molecular adaptations.⁴⁴ These biological “bottlenecks” effectively shield the malignant cell by either neutralizing the drug’s reactive species or severely restricting its entry into the intracellular environment.²² Broadly, these resistance mechanisms can be categorized into pre-target sequestration and impaired transport kinetics, both of which significantly diminish the drug’s cytotoxic potential.⁴⁵

Intracellular Thiol Sequestration and Neutralization

A primary cornerstone of cisplatin resistance is the inactivation of the drug by intracellular nucleophilic scavengers before it can interact with its primary target, nuclear DNA.²² Among these, glutathione (GSH) plays a definitive role. Due to its high affinity for the active sulfhydryl (-SH) group of GSH, cisplatin is often neutralized through the formation of GS-platinum complexes.³⁹ This sequestration is often facilitated by elevated levels of glutathione S-transferase (GST), an enzyme that catalyzes the conjugation of cisplatin to GSH. In resistant tumor phenotypes, this upregulated thiol system acts as a potent antioxidant shield, scavenging reactive oxygen species and effectively deteriorating chemotherapeutic efficiency by preventing the formation of DNA-platinum adducts.^{14,45}

Transport Pathway Downregulation: The Critical Role of LRRC8A

Beyond the metabolic neutralization of the drug, therapeutic failure is often rooted in the physical exclusion of cisplatin from the cell. Recent research has identified the leucine-rich repeat-containing protein 8A (LRRC8A)—a key component of the volume-regulated anion channel (VRAC)—as a vital mediator of cisplatin uptake.^{15,16} A direct correlation exists between LRRC8A downregulation and the development of cisplatin resistance across various malignancies, including head and neck squamous cell carcinomas and non-small cell lung carcinomas.^{16,17}

The loss of LRRC8A expression carries significant prognostic weight; patients exhibiting low LRRC8A or LRRC8D levels often face decreased overall survival, as even high cumulative doses of platinum-based therapy fail to reach therapeutic thresholds within the tumor.¹⁷ Furthermore, the absence of this protein impairs the apoptotic volume decrease (AVD). Since

AVD is a fundamental morphological requirement for initiating programmed cell death, the deficiency of LRRC8A provides a dual layer of protection for the tumor: it simultaneously reduces drug influx and inhibits the cellular machinery required for apoptosis.^{16,18}

The mechanisms for bypassing molecular resistance via nanotechnology are illustrated in Figure 2.

Thus, the main biological mechanisms contributing to cisplatin resistance in tumor cells include:

1. **Metabolic neutralization:** Elevated levels of intracellular thiol-containing species like glutathione (GSH) neutralize cisplatin by forming inactive platinum-thiol conjugates, which are then exported from the cell.^{1,3}
2. **Transport pathway downregulation:** Reduced expression of transporters, such as

LRRC8A, impairs cisplatin uptake, decreasing intracellular accumulation and efficacy.¹

3. **Enhanced DNA repair:** Tumor cells can increase their DNA repair capacity, diminishing cisplatin-induced DNA damage and apoptosis.¹
4. **Increased detoxification enzymes:** Up-regulation of enzymes such as GST facilitates the conjugation of cisplatin with GSH, further inactivating the drug.¹
5. **Altered apoptotic pathways:** Deficiencies in apoptotic mechanisms, such as impaired AVD, hinder programmed cell death in response to cisplatin.¹

These mechanisms collectively create a multifaceted resistance, reducing cisplatin's cytotoxicity.^{1,3}




Figure 2: Overcoming Cisplatin resistance: The nanotechnology solution.

Nanotechnology as a Precision Solution to Therapeutic Bottlenecks

Conventional cisplatin formulations often lack the molecular precision needed to overcome the complex biological barriers of resistance and systemic toxicity. To address these limitations, nanotechnology has emerged as a transformative frontier, offering sophisticated delivery systems that enhance the drug's therapeutic index. Among the most promising strategies is the development of cyclodextrin-based nanovesicles. These platforms leverage unique host-guest chemistry—where the hydrophobic cavity of the cyclodextrin molecule encapsulates the cisplatin—effectively improving the

drug's aqueous stability and significantly prolonging its circulation half-life.⁴

Historically, nanoparticle accumulation in malignant tissues relied primarily on the enhanced permeability and retention (EPR) effect, a passive targeting mechanism driven by the leaky vasculature of tumors. However, current clinical research is rapidly shifting toward active targeting and stimuli-responsive release.³ By engineering nanoparticles to release their payload only in response to specific triggers within the tumor microenvironment (such as pH shifts, enzymatic activity, or redox gradi-

ents) researchers can achieve high local cisplatin concentrations while sparing healthy renal and cardiac tissues.

Stimuli-responsive nanocarriers enhance targeted cisplatin delivery by releasing the drug in response to specific tumor microenvironment triggers, such as pH shifts, enzymatic activity, or redox gradients.¹ These mechanisms ensure high local drug concentrations within the tumor while minimizing systemic toxicity. For example, nanoparticles engineered to respond to acidic pH or tumor-specific enzymes can discharge cisplatin only upon reaching the tumor site, thereby improving therapeutic efficacy and reducing off-target effects.¹

A landmark success in this landscape is NC-6004 (Nanoplatin). In Phase Ib/II clinical trials, this micellar formulation demonstrated superior tolerability compared to free cisplatin. Notably, NC-6004 achieved a maximum tolerated dose nearly double that of the standard cisplatin regimen without inducing significant nephrotoxicity.¹⁰ This success illustrates the potential of nanomedicine to reopen the “surgical window” for compromised patients by maintaining oncological efficacy while preserving the patient’s physiological reserve.

This review synthesizes these advancements, focusing on the synergy between cyclodextrin engineering and green-synthesized metallic hybrids. By integrating these technologies, we propose a multimodal precision framework that

simultaneously addresses biological resistance mechanisms and the operational hurdles of clinical translation, ultimately refining the standard of care in cardiothoracic oncology.³⁷

Literature Review

Supramolecular Engineering and Characterization

The transition from conventional cisplatin to a precision nanomedicine platform relies on the sophisticated manipulation of supramolecular chemistry. By moving beyond covalent bonding and focusing on non-covalent molecular assemblies, researchers can engineer vehicles that safeguard the therapeutic payload until it reaches its intended site of action. The following sections detail the chemical principles of host-guest inclusion and the rigorous engineering required to maintain stable, sub-200 nm nanovesicles suitable for clinical application. Supramolecular Foundations: Host-Guest Inclusion and Development of Liposomal and Cyclodextrin-Complexed Formulations

At the heart of this delivery system lies the host-guest inclusion complex formed between cyclodextrins (CDs) and cisplatin. Cyclodextrins are cyclic oligosaccharides characterized by a unique toroid shape, possessing a hydrophilic exterior and a hydrophobic internal cavity.⁴ This amphiphilic nature allows them to act as molecular “hosts” for a variety of medicinal “guests” (Figure 3).¹⁹




Figure 3: Engineering the future of Cisplatin delivery: stealth nanovesicles

The encapsulation mechanism involves positioning the cisplatin molecule within the hydrophobic cavity of the CD. This process is primarily driven by non-covalent interactions, including van der Waals forces and hydrophobic effects, which form a stable yet reversible bond.^{2,4}

This structural arrangement confers significant chemical stability to the formulation. By shielding the cisplatin molecule within the cavity, the CD macrocycle protects it from premature hydrolysis—a common cause of systemic toxicity—and prevents non-specific protein binding during systemic circulation.¹ Among the common macrocycles utilized in this field, α -cyclodextrin and hydroxypropyl-cyclodextrin (HP-CD) are frequently preferred. These specific variants offer an optimal cavity size for the cisplatin molecule and significantly improve aqueous solubility, a critical hurdle in the formulation of platinum-based drugs.²

Development of Liposomal and Cyclodextrin-Complexed Formulations

The evolution of cisplatin-loaded liposomes (CP-LPS) modified with cyclodextrins represents a pivotal shift toward maximizing encapsulation efficiency and refining controlled-release kinetics. Historically, the clinical utility of cisplatin has been hampered by its rapid systemic clearance and significant off-target effects. To mitigate these issues, strategic modifications using α -cyclodextrin (α -CD) have been integrated into liposomal bilayers. This “double-layered” encapsulation approach enhances the stability and biodistribution of nanovesicles, allowing for selective accumulation within the tumor microenvironment while minimizing the systemic exposure that leads to nephrotoxicity and ototoxicity.^{2,3}

The engineering of these platforms typically uses the chloroform film method, combined with sonication, to ensure uniform particle formation. Research utilizing these techniques has achieved remarkable entrapment efficiencies of approximately 82–83%, a significant improvement over traditional liposomal preparations which often suffer from low loading capacity due to the moderate solubility of cisplatin.⁴

Morphological analysis and size characterization remain central to validating these formulations. While blank liposomes may average approximately 49 nm, the complexed α -CD-CP-LPS formulations naturally extend to over 100 nm due to the inclusion of the macrocyclic host-

guest complexes. Despite this increase in size, these vesicles maintain excellent physical stability, remaining viable at 4°C for over 3 months without significant aggregation or drug leakage.^{1,3}

To further optimize the pharmacokinetic profile, surface modification via PEGylation is employed. By coating the vesicles with polyethylene glycol (PEG), the system reduces opsonization by the reticuloendothelial system (RES), effectively granting the particles “stealth” properties. This prolonged circulation time facilitates superior tumor accumulation via the EPR effect, ensuring the therapeutic payload is delivered precisely to the malignancy.^{2,3}

In Vitro Release Kinetics and the Correlation with the “Surgical Window”

The success of a nanomedicine platform in a clinical CVT setting depends not only on successful encapsulation but also on the controlled-release profile of the drug. A rapid “burst release” can lead to systemic toxicity similar to free cisplatin, whereas a release that is too slow may fail to achieve therapeutic concentrations within the tumor. Characterizing these kinetics in vitro—typically via dialysis membrane methods in simulated physiological fluids (pH 7.4)—is essential for predicting how the formulation will behave in the perioperative environment.

Biphasic Release Profile

Cyclodextrin-complexed liposomes typically exhibit a characteristic biphasic release pattern. The initial phase involves a modest release of surface-associated cisplatin, followed by a prolonged, sustained release of the drug from the internal cyclodextrin-host complexes.

Clinical Correlation: This sustained release is vital for maintaining a steady therapeutic concentration, effectively extending the “optimal surgical window.” By providing a more stable oncological effect without the sharp peaks in plasma concentration that cause acute kidney injury (AKI), the surgeon can plan the procedure with greater confidence in the patient’s renal stability.^{2,10}

Stimuli-Responsive Release

Advanced formulations are now engineered to be stimuli-responsive, meaning the drug is released more rapidly in response to the specific conditions of the tumor microenvironment

(TME), such as lower pH (acidosis) or high redox potential (glutathione levels).

Targeted Cytotoxicity: In vitro studies have shown that these “smart” nanovesicles release their payload significantly faster at pH 5.5 (mimicking endosomal/lysosomal environments) than at physiological pH 7.4. This ensures that the cisplatin is discharged exactly where it is needed, further decoupling systemic toxicity from local efficacy.^{2,3}

Predicting Perioperative Stability

For the cardiothoracic surgeon, in vitro stability assays at 37°C in serum provide crucial data. Formulations that maintain their integrity under these conditions are less likely to cause sudden electrolyte imbalances or fluid management complications during hemodynamic fluctuations during cardiopulmonary bypass.^{11,12} By ensuring the drug remains sequestered within the nanovesicle during the most volatile stages of surgery, the risk of “overt nephrotoxicity” is substantially mitigated.

Advanced Targeting and Stimuli-Responsive Strategies

The therapeutic index of nanomedicines can be significantly optimized by developing stimuli-responsive liposomes engineered to release their payloads in response to specific localized cues within the pathological environment.²⁰ These “smart” platforms utilize endogenous factors, such as pH gradients, redox potential, and enzyme activity, to trigger drug release.²¹ For instance, pH-responsive liposomes often incorporate titratable lipids, such as cholesteryl hemisuccinate (CHEMS), or fusogenic lipids, such as DOPE, which undergo structural transitions in the acidic environments of tumors or endosomes to facilitate rapid cargo delivery.²¹ Similarly, redox-sensitive designs often employ disulfide bonds that remain stable in the bloodstream but are cleaved by the high intracellular glutathione concentrations (0.5–10 mM) found in cancer cells.²⁰

External stimuli, such as temperature, provide an additional layer of temporal and spatial control over drug delivery.²² Thermo-responsive platforms, most notably ThermoDox®, utilize localized hyperthermia (> 40–42°C) to trigger on-demand drug release directly at the target site.²³ These liposomes exploit the gel-to-liquid-crystalline phase transition temperature (T_m) of the lipid bilayer; at this critical point,

the membrane becomes highly permeable, allowing the encapsulated drug to rapidly penetrate surrounding tissue.²⁴ Clinical trials have demonstrated that combining mild hyperthermia with these thermosensitive carriers can enhance treatment efficacy by increasing vascular permeability and local blood flow.²⁵

However, the clinical translation of these advanced systems remains complex. While ligand-targeted liposomes (LTLs) offer the potential for enhanced selectivity by binding to overexpressed receptors, they introduce significant biological challenges.²⁶ The addition of targeting ligands can lead to non-specific protein binding (the formation of a protein corona) and ABC, which reduces the systemic half-life of the carrier.²⁶ Furthermore, high interstitial pressure and the dense extracellular matrix in solid tumors often hinder the deep penetration of these larger nanoparticles, even when high-affinity ligands are used.^{27,46} Overcoming these hurdles requires precise molecular engineering to balance stealth properties, such as PEGylation, with effective cellular uptake and triggered release.²⁶

Practical limitations also include the ABC phenomenon. Repeat dosing of PEGylated nanocarriers can trigger the production of anti-PEG IgM antibodies, which tag the particles for rapid destruction by the immune system. Additionally, the high interstitial pressure and dense extracellular matrix found in solid thoracic tumors can hinder the deep penetration of larger nanoparticles, even when high-affinity targeting ligands are used.³⁸

Molecular Engineering to Overcome Biological Barriers

To address the inherent conflict between high-affinity targeting and systemic stability, several precise molecular engineering strategies have been developed. These focus on masking the targeting ligands during circulation and optimizing the “stealth” layer to prevent the ABC phenomenon and non-specific protein adsorption.

“Hidden” or Cleavable PEG Shields

A primary challenge with ligand-targeted liposomes is that the ligands themselves can be recognized by the mononuclear phagocyte system, leading to rapid sequestration in the liver and spleen. To counter this, researchers utilize sheddable PEG layers.

Mechanism: Targeting ligands are attached to the lipid bilayer, but a longer, protective PEG chain is conjugated via a stimuli-responsive bond (e.g., a pH-sensitive hydrazone or a redox-sensitive disulfide linker).

Function: During circulation, the long PEG chains sterically mask the ligands, ensuring a “stealth” profile. Upon entering the acidic or reductive environment of the tumor, the PEG layer “sheds,” exposing the ligands for high-affinity receptor binding and cellular uptake.²⁸

Tuning Ligand Density and Orientation

The degree of protein corona formation—which contributes to the ABC effect—is highly dependent on ligand density.

The “Goldilocks” Principle: If ligand density is too low, the targeting effect is lost. If it is too high, the liposome is rapidly cleared because the dense protein cluster (opsonins) signals for immune destruction.

Site-Specific Conjugation: Engineering ligands (such as nanobodies or scFv fragments) to bind at specific orientations ensures that their binding sites remain functional while minimizing exposure of hydrophobic regions that typically attract plasma proteins.⁴⁷

Zwitterionic Polymer Coatings

As an alternative to traditional PEGylation, zwitterionic polymers (e.g., poly(carboxybetaine)) have emerged as a robust engineering tool.

These polymers create a highly hydrated layer through strong ionic solvation, which is more effective than PEG at resisting protein adsorption. Unlike PEG, which can sometimes trigger anti-PEG IgM antibodies (the primary cause of the ABC phenomenon upon repeat dosing), zwitterionic coatings are generally less immunogenic, allowing multiple administrations without loss of circulation time.⁴⁸

Future Outlook: The Next Generation of Stimuli-Responsive Nanomedicines

The evolution of liposomal technology from passive carriers to “smart” stimuli-responsive platforms represents a paradigm shift in precision oncology. By integrating molecular engineering—such as sheddable PEG shields and zwitterionic coatings—researchers are successfully navigating the biological trade-offs between systemic stability and site-specific activation.^{28,48} While challenges such as the ABC phenomenon remain significant, the transition toward non-immunogenic materials and precise ligand orientation offers a clear path to improve the therapeutic index of highly potent payloads.³¹

The table below synthesizes the core strategies discussed, mapping each engineering approach to its primary mechanism, advantages, and associated literature (Table 1).

Table 1 Synthesis of Molecular Engineering Strategies for Enhanced Targeting

Strategy	Primary Mechanism	Clinical Advantages	Key References
Sheddable PEG Shields	Detachment of PEG chains via local pH or enzymatic triggers.	Masks ligands during circulation; exposes them only at the pathological site.	28
Ligand Density Optimization	Precise control over the number and orientation of surface ligands.	Minimizes the "protein corona" effect and reduces immune recognition.	29
Zwitterionic Coatings	Replacement of PEG with super-hydrophilic, charge-neutral polymers.	Eliminates anti-PEG IgM response; superior resistance to protein adsorption.	30
Stimuli-Responsive Release	Phase transition or bond cleavage triggered by hyperthermia or pH.	Enhances spatial control and maximizes local drug concentration.	31

Looking forward, the clinical success of these advanced targeting strategies will likely depend on patient-stratification—identifying individuals whose unique tumor microenvironments (e.g., specific enzyme expression levels or interstitial pressure profiles) are most compatible

with a given stimuli-responsive mechanism. As molecular engineering continues to refine the interface between synthetic nanocarriers and complex biological systems, the goal of achieving “on-demand” drug delivery with minimal

systemic toxicity moves closer to standard clinical practice.

The Clinical Paradox of Cisplatin in Thoracic Oncology

In the landscape of thoracic oncology, cisplatin therapy is defined by a profound “clinical paradox.” While it remains one of the most potent and foundational chemotherapeutic agents, its high cytotoxicity is frequently offset by systemic limitations that limit dose escalation and result in incomplete antitumor responses. Beyond its role in NSCLC, cisplatin is a standard-of-care treatment for ovarian, testicular, and head-and-neck cancers; however, its clinical utility is continually constrained by its narrow therapeutic index.⁵

The paradox lies in the necessity of high-dose regimens to overcome inherent or acquired tumor resistance, which simultaneously precipitates severe, dose-limiting toxicities. In cardiothoracic surgery, this creates a significant management dilemma. Systemic toxicity, particularly nephrotoxicity and ototoxicity, remains the primary barrier to maximizing the drug’s therapeutic potential. For the surgeon, the emergence of subclinical renal impairment during induction chemotherapy can alter the patient’s physiological reserve, potentially closing the “surgical window” by increasing the risks associated with hemodynamic shifts and fluid management during major thoracic procedures.^{7,10}

Furthermore, the drug’s lack of specificity results in high concentrations in healthy tissues, such as renal proximal tubular cells, while tumor concentrations may remain suboptimal due to poor vascularization or metabolic bottlenecks.⁶ This mismatch necessitates a shift toward precision delivery systems that can resolve this paradox by decoupling systemic toxicity from oncological efficacy.

The development of cisplatin resistance is a complex biological defense mechanism that involves a synergistic “pincer movement” within the cell: the metabolic neutralization of the drug and the physical restriction of its entry. At the metabolic level, resistant tumor populations frequently exhibit elevated levels of intracellular thiol-containing species, most notably glutathione (GSH). These nucleophilic molecules act as metabolic scavengers, intercepting cisplatin before it can reach nuclear DNA, forming

inactive platinum-thiol conjugates that are subsequently exported from the cell.⁴⁴

The key resistance mechanisms limiting cisplatin efficacy include metabolic neutralization by intracellular thiol species, such as glutathione (GSH), which inactivate the drug by forming conjugates that are exported from the cell, and decreased drug uptake due to downregulation of transporters.³ Additionally, tumor cells can enhance DNA repair mechanisms and develop cellular defense pathways that diminish cisplatin-induced cytotoxicity.³ Nanomedicine can address these resistance mechanisms by enabling targeted delivery and stimuli-responsive release of cisplatin within the tumor microenvironment. For example, cyclodextrin-based nanovesicles encapsulate cisplatin, improving its stability and circulation time, and can be engineered to release the drug in response to tumor-specific triggers such as pH or enzymatic activity.³ This approach increases local drug concentration and bypasses resistance pathways. It reduces systemic toxicity, thereby enhancing therapeutic efficacy.⁴¹

Simultaneously, resistance is driven by the significant downregulation of critical transport pathways, specifically the Copper Transporter 1 (CTR1) and the Leucine-rich repeat-containing protein 8A (LRRC8A) axis. While CTR1 has traditionally been identified as the primary influx transporter for cisplatin, recent evidence indicates that LRRC8A is an essential mediator of drug uptake via VRAC. The deficiency of these proteins directly correlates with therapeutic failure and poor clinical prognosis, as the “locked” cell membrane prevents the drug from reaching a minimum inhibitory concentration.^{17,18}

Nanoparticles have shown remarkable promise in overcoming these molecular barriers. By utilizing endocytic pathways, nanomedicine platforms can bypass both typical efflux pumps and the downregulated CTR1/LRRC8A transporters. Once internalized, these nanoparticles can be engineered to modulate cellular pathways—such as depleting intracellular GSH stores—thereby restoring chemosensitivity in refractory cell populations and ensuring that the therapeutic payload reaches its genomic target.^{1,3}

Advanced Characterization: Validating the Sub-200 nm Threshold

To ensure that cyclodextrin-based nanovesicles effectively exploit the EPR effect while maintaining systemic stability, rigorous physical characterization is essential. For clinical translation, a particle size threshold of sub-200 nm is generally required to avoid rapid clearance by the spleen and to ensure efficient extravasation into tumor tissues. The following techniques are the gold standards for verifying these dimensions and the nanomedicine's structural integrity.

Dynamic Light Scattering (DLS)

Dynamic Light Scattering, also known as Photon Correlation Spectroscopy, is the primary technique used to determine the hydrodynamic diameter and the Polydispersity Index (PDI) of the nanovesicles in a liquid medium. DLS measures the Brownian motion of particles; smaller particles move faster, leading to more rapid fluctuations in the scattered light intensity.

A low PDI (typically <0.2) indicates a uniform particle population, which is crucial for predictable pharmacokinetics. DLS provides a statistically significant “bulk” measurement of the entire sample, ensuring that the majority of the vesicles fall within the desired therapeutic range.^{2,4}

Transmission Electron Microscopy (TEM)

While DLS provides an indirect measurement of size based on light scattering, TEM offers direct visual evidence of the vesicles' morphology and actual size. By using an electron beam to image the sample, TEM can reveal the spherical shape of cyclodextrin liposomes or the internal structure of metallic-hybrid nanoparticles.

Surface Analysis: High-resolution TEM can also verify the presence of surface modifications, such as the “corona” created by PEGylation, which is vital for the “stealth” properties of the delivery system.^{1,3}

Zeta Potential Analysis

Zeta potential measures the **electrokinetic potential** at the nanoparticle's surface. It is a critical indicator of the colloidal suspension's physical stability.

Stability Prediction: A high absolute zeta potential (typically) creates sufficient electrostatic repulsion to prevent particle aggregation. For the cardiothoracic surgeon, this ensures that the formulation remains a stable suspension during storage and administration, thereby reducing the risk of microemboli during infusion.^{2,4}

Dose-Limiting Nephrotoxicity and the Necessity of Clinical Monitoring

The “clinical paradox” of cisplatin is most visible in its dose-limiting nephrotoxicity. While higher cumulative doses are statistically associated with better oncological outcomes in thoracic malignancies, the risk of Acute Kidney Injury (AKI) increases exponentially beyond a threshold of 50–100 mg/m² per cycle. This creates a ceiling on therapeutic intensity, often leaving subclinical residual disease.

The renal-sparing profile of nanocarriers allows for a more aggressive integration of intraoperative decision-making. By reducing subclinical renal impairment, clinicians can utilize goal-directed fluid therapy (GDFT) to maintain optimal renal perfusion without the “double hit” of cisplatin-induced baseline damage. This allows the surgeon to titrate vasopressors and manage fluid balance with greater precision during major thoracic shifts, such as pneumonectomy.³⁹

Pathophysiological Triggers of AKI

Cisplatin-induced nephrotoxicity primarily targets the S3 segment of the renal proximal tubules. The drug is transported into these cells by Copper Transporter 1 (CTR1) and organic cation transporters, where it reaches concentrations five times higher than in the serum. Once intracellular, cisplatin triggers oxidative stress, mitochondrial dysfunction, and proinflammatory cytokine release, leading to tubular necrosis and a subsequent drop in the GFR.^{5,8}

Clinical Monitoring: Beyond Serum Creatinine

For patients slated for major thoracic surgery, traditional monitoring of serum creatinine is often insufficient, as it is a “lagging indicator” that only rises after significant renal damage has occurred.

Creatinine Clearance: Calculated via the Cockcroft-Gault equation or measured via 24-hour urine collection, provides a more accurate assessment of the “surgical window.” A drop

below 60 mL/min typically necessitates dose reduction or a delay in surgery.

Electrolyte Surveillance: Monitoring for hypomagnesemia and hypokalemia is critical. Cisplatin induces “renal magnesium wasting,” and the resulting electrolyte imbalances can provoke cardiac arrhythmias—a high-risk complication during procedures like pneumonectomy where cardiac displacement occurs.^{10,41}

Fluid Balance and Goal-Directed Therapy: Intraoperative monitoring focuses on maintaining optimal renal perfusion. The use of GDFT aims to avoid the “double hit” of cisplatin-induced baseline damage and the hemodynamic fluctuations of cardiopulmonary bypass or major thoracic shifts.^{11, 12}

The Surgical Dilemma of the “Hit”

If monitoring reveals a significant nephrotoxic “hit” during induction therapy, the surgeon faces a compromised patient. Reduced renal reserve limits the use of certain perioperative medications (like NSAIDs for pain management) and complicates fluid resuscitation. Effectively, the dose-limiting nature of cisplatin does not just affect the oncologist’s prescription—it fundamentally limits the surgeon’s technical options and increases the risk of post-operative pulmonary edema due to fluid overload.^{9,11}

Green Nanotechnology: Phytochemical-Mediated Metallic Synthesis

A burgeoning frontier in nanomedicine is the shift toward green nanotechnology, which prioritizes the use of biologically derived reducing and stabilizing agents over hazardous chemical precursors. This approach leverages the complex secondary metabolites found in plant extracts—such as those from *Olea europaea* (Olive) or *Azadirachta indica* (Neem)—to facilitate the synthesis of metallic nanoparticles, particularly silver, gold, and platinum hybrids. These phytochemicals, including polyphenols, flavonoids, and terpenoids, serve a dual role: they reduce metallic ions into stable nanoparticles while simultaneously acting as capping agents that improve biocompatibility and reduce systemic toxicity.^{3,13}

Beyond their role as delivery vehicles, these green-synthesized nanoparticles exhibit inherent broad-spectrum antimicrobial and anticancer properties. In malignant cells, they have been shown to induce apoptosis by generating

oxidative stress. By triggering the overproduction of reactive oxygen species, these metallic hybrids disrupt mitochondrial membrane potential and initiate programmed cell death pathways. This oxidative mechanism is particularly valuable when combined with cisplatin, as it may sensitize refractory tumor populations that have otherwise developed resistance to traditional DNA-damaging pathways.^{1,13}

For clinical translation, green synthesis offers a significant solution to the “operational hurdle.” By eliminating toxic solvents and high-energy processes, these methods produce nanoparticles with enhanced safety profiles, making them more suitable for the delicate physiological environments encountered in cardiothoracic surgery.² This synergy between green chemistry and precision medicine ensures that the resulting nanoplateforms are not only oncologically effective but also environmentally and biologically sustainable.

Pharmacokinetic Optimization and the EPR Effect

The transition of cisplatin from a small-molecule drug to a nanoparticle-based system fundamentally alters its pharmacokinetic profile, moving from rapid systemic clearance to a prolonged, tumor-targeted circulation. A cornerstone of this optimization is the EPR effect, a physiological phenomenon unique to the tumor microenvironment. In rapidly growing tumors, the neo-vasculature is structurally defective, characterized by large fenestrations or “leaky” walls. Nanoparticles, typically engineered in the 10–200 nm range, can extravasate through these gaps into the tumor interstitium. Furthermore, because tumors often lack functional lymphatic drainage, these particles are not efficiently cleared, leading to significant passive accumulation compared to healthy tissues.^{3,5}

However, the EPR effect can only be exploited if the nanoparticles remain in systemic circulation long enough to reach the tumor site. To achieve this, surface modifications are essential to bypass the body’s natural defense mechanisms. PEGylation—the covalent attachment of polyethylene glycol (PEG) chains to the nanoparticle surface—is the most widely utilized strategy. This modification creates a “stealth” shield that reduces opsonization, the process by which serum proteins tag foreign

particles for destruction. By preventing detection by the RES, particularly the macrophages in the liver and spleen, PEGylation significantly prolongs the drug's half-life.^{2,13}

For the cardiothoracic surgeon, this pharmacokinetic shift is clinically significant. By ensuring the drug accumulates preferentially in thoracic malignancies rather than the renal cortex, these engineered platforms minimize the nephrotoxic “hit” that often complicates the perioperative period, thereby preserving the patient's physiological reserve for surgery.^{9,12}

Theranostic Integration and Real-Time Surgical Monitoring

The evolution of precision oncology has moved beyond simple drug delivery toward theranostics—a dual-function paradigm that integrates diagnostic imaging with therapeutic intervention within a single platform. This integration is particularly transformative for cardiothoracic surgery, enabling real-time monitoring of treatment response and precise mapping of tumor margins before or even during an operation. By using nanoparticles as contrast agents, clinicians can visualize the drug's biodistribution and confirm its accumulation within the thoracic malignancy, ensuring that the “surgical window” is optimized based on actual physiological data rather than generalized timelines.^{2,13}

Gold nanoparticles (AuNPs) have emerged as ideal candidates for this multimodal role. Their unique localized surface plasmon resonance provides exceptional optical properties, making them highly effective contrast agents for computed tomography (CT) and surface-enhanced Raman scattering (SERS) imaging. Furthermore, the facile surface functionalization of gold enables simultaneous attachment of cisplatin, targeting ligands (e.g., antibodies or peptides), and PEG chains. This versatility enables multimodal therapies, in which the AuNPs can serve as both the delivery vehicle for chemotherapy and sensitizers for photothermal therapy (PTT), which uses near-infrared light to induce localized hyperthermia and further weaken resistant tumor populations.^{3,13}

Gold nanoparticles (AuNPs) have emerged as ideal candidates for this multimodal role. Their unique localized surface plasmon resonance provides exceptional optical properties, making

them highly effective contrast agents for computed tomography (CT) and surface-enhanced Raman scattering (SERS) imaging. Furthermore, the facile surface functionalization of gold enables simultaneous attachment of cisplatin, targeting ligands (e.g., antibodies or peptides), and PEG chains. This versatility enables multimodal therapies, in which the AuNPs can serve as both the delivery vehicle for chemotherapy and sensitizers for photothermal therapy (PTT), which uses near-infrared light to induce localized hyperthermia and further weaken resistant tumor populations.^{3,13}

For the CVT surgeon, theranostic integration offers a path toward “image-guided surgery.” The ability to monitor tumor regression or renal function stability in real time enables more precise perioperative decision-making.

By reducing the guesswork associated with systemic drug toxicity, these platforms ensure that patients undergoing major thoracic shifts—such as a pneumonectomy—are physiologically prepared for the hemodynamic demands of the procedure.^{2,11}

The Translational Gap: Regulatory and Manufacturing Hurdles

Despite the overwhelming success of nanomedicine in preclinical environments, the transition from “bench to bedside” remains a significant challenge. This translational gap is primarily driven by the complexities inherent in scaling up nanoparticle production from small laboratory batches to industrial-scale manufacturing. Ensuring manufacturing reproducibility—where every batch maintains identical particle size, drug loading efficiency, and surface charge—is a monumental task for complex, multi-component systems like cyclodextrin-metallic hybrids. Furthermore, regulatory hurdles imposed by agencies such as the FDA and EMA require exhaustive characterization and safety data that often exceed those for small-molecule drugs, significantly increasing the cost and timeline for clinical implementation.^{2,5}

However, the clinical landscape is beginning to stabilize as pioneers provide a roadmap for future development. A notable success in this domain is NC-6004 (Nanoplatin), a micellar cisplatin formulation that has overcome these hurdles. Clinical trials have demonstrated that NC-6004 can achieve a maximum tolerated dose nearly double that of standard cisplatin

without the traditional “hits” of significant neuro- or nephrotoxicity.¹⁰ This achievement proves that with the right engineering and regulatory focus, precision formulations can bypass the physiological bottlenecks that currently limit the CVT surgical window.

For the cardiothoracic surgeon, bridging this gap means more than just having a “safer” drug; it means the potential for induction therapies that do not compromise the patient’s ability to survive a major thoracic procedure. As manufacturing processes become more standardized and green synthesis methods reduce toxic chemical waste, the roadmap provided by formulations such as NC-6004 will likely lead to a new standard of care in surgical oncology.^{3,11}

While NC-6004 provides a clinical roadmap, significant regulatory and manufacturing hurdles remain. Manufacturing reproducibility is a primary challenge, as every industrial-scale batch must maintain identical particle size and drug loading efficiency. Furthermore, regulatory agencies such as the FDA and EMA require extensive safety data for multi-component systems, which can exceed the requirements for small-molecule drugs. These complexities create a translational gap that currently restricts the routine implementation of these platforms in general clinical practice.⁴⁰

A detailed overview of molecular resistance mechanisms and corresponding nanotherapeutic strategies is presented in Table 2.

Table 2: Cisplatin Resistance Mechanisms and Nanotechnology-Based Solutions

Resistance Mechanism / Clinical Limitation	Impact on Therapeutic Outcome	Nanotechnology Intervention
Intracellular Thiol Sequestration (GSH) ^{1,3,20}	Cisplatin is neutralized by glutathione (GSH) to form inactive platinum-thiol conjugates. ²²	Host-Guest Inclusion: Cyclodextrins encapsulate cisplatin, shielding it from premature hydrolysis and metabolic scavengers ¹
Transport Pathway Downregulation (LRRC8A/CTR1)	Reduced expression of LRRC8A and CTR1 restricts drug entry, leading to suboptimal intracellular concentrations ^{17, 18}	Endocytic Internalization: Nanoparticles utilize endocytic pathways to bypass downregulated transporters entirely.
Dose-Limiting Nephrotoxicity ³	Accumulation in renal proximal tubules causes acute kidney injury (AKI), closing the "surgical window". ^{5, 7, 8,}	Micellar Delivery (NC-6004): Targeted nanoplatin reduces nephrotoxicity ¹⁰ , allowing for higher therapeutic doses (up to 135 mg/m ²).
Systemic Instability & Rapid Clearance	Non-specific protein binding and rapid clearance result in significant off-target effects and a narrow therapeutic index ¹ .	PEGylation & Stealth Coatings: Surface modifications prolong circulation half-life and facilitate tumor accumulation via the EPR effect. ^{35, 36}
Metabolic Resistance & DNA Repair ^{14, 22}	Upregulated thiol systems act as antioxidant shields, preventing the formation of lethal DNA-platinum adducts ^{14, 22, 39}	ROS-Inducing Metallic Hybrids: Green-synthesized silver/gold hybrids trigger oxidative stress to sensitize refractory tumor populations ^{1, 13}

Table 2 delineates the "clinical paradox" of cisplatin, i.e., the conflict between its potent DNA-damaging efficacy and its severe systemic limitations, and it proposes nanotechnology solutions. It also maps specific biological hurdles, including thiol-mediated sequestration and transport downregulation, against advanced engineering solutions such as cyclodextrin-based host-guest inclusion and stimuli-responsive nanovesicles. Technical benchmarks, such as an entrapment efficiency of 82–83% and physical stability for over three months, are highlighted as critical requirements for clinical translation. Furthermore, the table emphasizes the role of platforms like NC-6004 in increasing the maximum tolerated dose nearly twofold without inducing significant renal impairment. Ultimately, these interventions facilitate "surgical reclaimability" by preserving the patient’s physiological reserve and maintaining the "optimal surgical window" required for curative resection.

Precision Nanomedicine: Navigating the Surgical Frontier in Thoracic Oncology

The management of solid malignancies, particularly NSCLC, is currently defined by a profound “clinical paradox”. While cisplatin remains a foundational cornerstone of systemic therapy, its exceptional potency is frequently offset by a dangerously narrow therapeutic index. From the perspective of a cardiothoracic (CVT) surgeon, the dose-limiting nephrotoxicity of platinum-based agents is more than a side effect; it is a physiological barrier that can prematurely close the “optimal surgical window”. When a patient’s renal reserve is depleted by the systemic “first-hit” of chemotherapy, the risks of perioperative complications increase, potentially rendering a technically resectable tumor surgically unviable.

The clinical translation of these platforms relies on rigorous technical benchmarks, including entrapment efficiencies of 82–83% and physical stability for over 3 months. As highlighted in Table 2, the implementation of platforms like NC-6004 (Nanoplatin) represents a landmark shift, increasing the maximum tolerated dose nearly twofold without inducing significant renal impairment. Ultimately, these precision interventions facilitate “surgical reclaimability” by preserving the patient’s physiological reserve for the curative operation.

Discussion

Integrating cyclodextrin-based platforms with green-synthesized metallic nanoparticles offers a promising avenue to combine host-guest inclusion with metal-mediated photothermal effects. The incorporation of antioxidant phytochemicals, such as *Acacia hydaspica*, into the matrix further ensures protection of vital organs, specifically reducing nephrotoxicity. Achieving uniform size distributions (100–200 nm) through systematic optimization will be pivotal for scaling these hybrid vesicles toward clinical use. Future investigations must explore functionalizing the vesicle surface with tumor-specific ligands to further refine the therapeutic index.

The following discussion centers on three pivotal intersections of surgical practice and oncological science:

The Impact of Nanomedicine on “Surgical Reclaimability”

In the current paradigm of thoracic oncology, “surgical reclaimability” refers to the clinical process of transforming patients previously deemed unfit for resection—due to poor physiological reserve or high-risk profiles—into viable surgical candidates through targeted neoadjuvant intervention. This concept is particularly critical in NSCLC, where the “surgical window” often closes not because of tumor progression, but because the systemic “first-hit” of conventional induction chemotherapy depletes the patient’s renal and cardiovascular reserve.³³

Primary obstacles to the reclaimability of standard cisplatin include its 25–35% incidence of dose-limiting nephrotoxicity.⁸ By utilizing NC-6004 (Nanoplatin), the pharmacokinetic profile of cisplatin is fundamentally altered. Clinical evidence indicates that NC-6004 can achieve a maximum tolerated dose (MTD) of 135 mg/m² without inducing clinically significant nephrotoxicity.¹⁰ This safety profile allows induction in patients with borderline renal function (eGFR 45–60 mL/min) and preserves performance status.^{10,34}

NC-6004 (Nanoplatin) improves upon traditional cisplatin by reducing systemic toxicity, particularly nephrotoxicity and neurotoxicity, while maintaining or enhancing therapeutic efficacy. Its nanoparticle formulation enables targeted delivery and controlled release of cisplatin, helping minimize off-target effects and improve tolerability. Clinical trials have demonstrated that NC-6004 can be administered at nearly twice the standard cisplatin dose without significant adverse effects, thereby expanding the therapeutic window and enabling higher doses for better tumor control.^{1,2} This advancement facilitates the “reclaimability” of patients who might otherwise be unfit for high-dose cisplatin therapy, making it more suitable for clinical application, especially in settings requiring aggressive treatment with manageable toxicity profiles.^{41,42}

NC-6004 (Nanoplatin) represents a landmark success in transitioning from bench to bedside, having completed Phase Ib/II clinical trials. Empirical evidence from these trials demonstrates that this micellar formulation achieves an MTD of 135 mg/m². This dose is nearly double the standard cisplatin regimen of 75 mg/m² per cycle. Critically, NC-6004 achieved these therapeutic thresholds without inducing signif-

icant nephrotoxicity or neurotoxicity, demonstrating superior tolerability compared to free cisplatin.^{42,43}

The “Stealth vs. Targeting” Dilemma and Regulatory Viability

A central challenge is the “Stealth vs. Targeting” paradox. To survive circulation, a nanoparticle requires a dense “stealth” coating (PEG), which often creates a steric barrier that prevents targeting ligands from binding to tumor receptors.^{26,44}

Sheddable PEG Layers: Benefit from an established regulatory roadmap but face risks of premature shedding and immune-mediated clearance.^{26,28}

Zwitterionic Coatings: Superior in bypassing the anti-PEG IgM response, but face a larger “translational gap” as they are categorized as New Chemical Entities.^{30,31,35}

For clinical trials, sheddable PEG platforms currently offer a more viable regulatory path, while zwitterionic coatings represent the robust frontier for repeat-dosing regimens.³⁶

Sheddable PEG Layers: The Controlled-Release Pathway

Sheddable PEG layers attempt to resolve this by utilizing stimuli-responsive linkers (e.g., pH-sensitive hydrazone or enzyme-cleavable peptides) that detach only upon reaching the tumor microenvironment (TME).²⁸

Viability Analysis: From a regulatory perspective, PEGylated systems benefit from decades of clinical data. The FDA has already approved multiple PEGylated products (e.g., Doxil®, Onivyde®), which provide a clear CMC (Chemistry, Manufacturing, and Controls) roadmap for manufacturers. However, the complexity of the “shedding” trigger adds a layer of regulatory scrutiny regarding the reproducibility of the stimulus-response mechanism across different patient populations.²⁶

Limitation: The primary risk is premature shedding in systemic circulation, which would expose the targeting ligands and trigger ABC.³¹

Zwitterionic Coatings: The “Stealth 2.0” Pathway

Zwitterionic polymers, such as poly(carboxybetaine), offer a fundamentally different approach. Instead of a temporary shield, they provide a permanent hydration layer that is intrinsically resistant to protein adsorption.³⁰

Viability Analysis: The most significant clinical advantage of zwitterions is their ability to bypass the anti-PEG IgM immune response. Since many patients have pre-existing anti-PEG antibodies from common consumer products, zwitterionic platforms may offer more predictable pharmacokinetics in human trials.^{31,35}

Limitation: Despite their scientific superiority in preventing the ABC phenomenon, zwitterions face a “translational gap” because regulatory agencies consider them “New Chemical Entities” (NCEs). This requires more extensive toxicology and safety data than modifying an existing PEG-based platform.³⁶

Synthesis for Clinical Trials

For a CVT surgeon looking to implement these in induction therapy, the choice depends on the trade-off between innovation and speed to clinic. While zwitterionic coatings offer a more robust physiological profile for repeat dosing regimens, sheddable PEG platforms currently offer a more viable regulatory path due to the established safety profile of PEG-lipid conjugates.

Real-Time Pharmacokinetic Monitoring and Intraoperative Decision-Making

Theranostic nanoparticles provide a continuous feedback loop that is invaluable during high-stakes thoracic procedures. During major thoracic shifts, the kidneys often face a “double hit” of induction oxidative stress and intraoperative hemodynamic fluctuations.⁴⁷

Utilizing gold nanoparticles (AuNPs), surgeons can visualize actual drug accumulation in the renal cortex via intraoperative CT or SERS imaging.⁴⁷ This allows for GDFT tailored to the patient’s renal state. Surgeons can titrate vasopressors to maintain renal perfusion pressure or restrict fluids to prevent post-pneumonectomy pulmonary edema, while ensuring sufficient volume to flush cisplatin nanovesicles through the proximal tubules.^{9,11,12}

A synthetic overview of molecular resistance mechanisms and corresponding nanotherapeutic strategies in Table 2. This table delineates the “clinical paradox” of cisplatin—the conflict between its potent DNA-damaging efficacy and its severe systemic limitations—and proposes nanotechnology as a precision solution. It maps specific biological hurdles, including thiol-mediated sequestration and transport downregulation, against advanced engineering solutions

such as cyclodextrin-based host-guest inclusion and stimuli-responsive nanovesicles. Technical benchmarks, such as an entrapment efficiency of and physical stability for over three months, are highlighted as critical requirements for clinical translation. Furthermore, the table highlights the role of platforms like NC-6004 in

nearly doubling MTD without causing significant renal impairment. Ultimately, these interventions facilitate “surgical reclaimability” by preserving the patient’s physiological reserve and maintaining the “optimal surgical window” required for curative resection.

Conclusion

The evolution of cisplatin from a conventional small-molecule drug to a precision nanomedicine platform represents a paradigm shift in the management of thoracic malignancies. This review has demonstrated that the “clinical paradox” of cisplatin—the conflict between its DNA-damaging efficacy and its systemic toxicity—can be resolved through sophisticated supramolecular engineering. By utilizing cyclodextrin-based host-guest inclusion and stimuli-responsive liposomal carriers, it is now possible to safeguard the therapeutic payload from premature hydrolysis and non-specific sequestration in the renal proximal tubules.

From a surgical perspective, these advancements are transformative. The ability to reduce subclinical nephrotoxicity through platforms like NC-6004 directly expands the “optimal surgical window,” allowing the “reclaimability” of patients who would otherwise be deemed too fragile for major resection. Furthermore, the development of theranostic nanoparticles offers the prospect of real-time, intraoperative pharmacokinetic monitoring, enabling surgeons to titrate fluid management and vasopressor support with unprecedented precision.

Despite the remaining regulatory and manufacturing hurdles associated with the “stealth vs. targeting” dilemma, the trajectory of clinical oncology is moving toward a more personalized, image-guided approach. As green nanotechnology and precision engineering continue to refine the interface between synthetic nanocarriers and complex human physiology, the goal of achieving a resection with minimal systemic burden moves from a theoretical ideal to a clinical reality. Ultimately, these “smart” DDS are not merely oncological tools; they are surgical necessities that preserve the patient’s physiological reserve for the most critical phase of their treatment: the curative operation.

Data Availability Statement: Data sharing does not apply to this article as no new datasets were generated or analyzed during the current study. This is a comprehensive review of existing literature, and all data discussed are available within the cited primary research articles.

Statement of AI use: During the preparation of this manuscript, the author used AI-assisted tools at specific and clearly defined stages of the editorial workflow, with full human oversight maintained throughout. No AI tool was used to generate, fabricate, or substitute original research data or scientific conclusions.

Stage 1 — Gap Identification (Humata): Following completion of the initial manuscript draft, Humata was used solely to identify potential argumentative gaps and sections requiring additional supporting evidence. All suggestions were critically evaluated and independently verified by the author; only those determined to be scientifically appropriate and accurate were incorporated into the revised draft.

Stage 2 — Proofreading and Condensation (Google Gemini and Perplexity AI): Google Gemini and Perplexity AI were used independently in a cross-comparative manner for proofreading, identification and removal of redundant content, and language condensation. All AI-suggested revisions were reviewed, critically assessed, and finalized solely by the author.

Stage 3 — Content Verification and Reference Reorganization (Claude, Anthropic): Following content condensation, Claude (Anthropic) was used to verify content integrity and to assist with reorganization of the reference list to reflect the updated manuscript structure. All reference entries were confirmed for accuracy by the author.

Figures — Digital Illustration (NotebookLM): The four figures in this manuscript were produced using NotebookLM strictly as a digital drawing and illustration tool. NotebookLM was not used as a generative AI image tool; all visual content was designed and directed entirely by the author based on original scientific concepts developed within this work, and does not reproduce or derive from any external copyrighted visual material.

The author affirms that: (i) no AI tool holds or is attributed authorship of any part of this manuscript; (ii) no AI tool was used to generate original research data, hypotheses, or scientific interpretation; (iii) all AI-assisted content was subject to critical human review and editorial judgment at every stage; and (iv) the author accepts sole and full responsibility for the accuracy, integrity, and originality of the entire manuscript, including all AI-assisted sections, and for any ethical implications arising from the use of AI tools in this publication.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Acknowledgments: The author gratefully acknowledges the School of Pharmaceutical Sciences, University of Phayao, for the institutional support and resources that made this research possible. Special thanks are also extended to the OSF HealthCare Cardiovascular Institute – Vascular & Cardiothoracic Surgery for their profound clinical insights regarding the surgical window and perioperative patient management.

Conflicts of Interest: The author declares that she has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. For a written statement, contact the editorial office: editor@precisionnanomedicine.com.

Quote this article as Panijapatr Wasubhadtanasaka, Precision Nanomedicine in Cardiothoracic Oncology: Overcoming the Clinical Paradox of Cisplatin through Supramolecular and Stimuli-Responsive Engineering, *Precis Nanomed*. 2026;9(2):1815-1833, <https://doi.org/10.33218/001c.161262>

COPYRIGHT NOTICE ©The Author(s) 2026. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Ling X, Chen X, Riddell IA, et al. Glutathione-scavenging poly(disulfide amide) nanoparticles for the effective delivery of Pt(IV) prodrugs and reversal of cisplatin resistance. *Nano Lett*. 2018;18(8):4618-4626. doi:10.1021/acs.nanolett.8b01924
2. Wasubhadtanasaka P. In vitro characterization of beta-cyclodextrin liposomal formulation of cisplatin nanomedicine. *Precis Nanomed*. 2024;7(3):1322-1337. doi:10.33218/001c.124209
3. Siemer S, Bauer T, Scholz P, et al. Targeting cancer chemotherapy resistance by precision medicine-driven nanoparticle-formulated cisplatin. *ACS Nano*. 2021;15(11):18541-18555. doi:10.1021/acsnano.1c08632
4. Bose R, Jayawant M, Raut RW, et al. Cyclodextrin nanoparticles in targeted cancer theranostics. *Front Pharmacol*. 2023;14:1218867. doi:10.3389/fphar.2023.1218867
5. Dugbartey GJ, Peppone LJ, de Graaf IA. An integrative view of cisplatin-induced renal and cardiac toxicities: molecular mechanisms, current treatment challenges and potential protective measures. *Toxicology*. 2016;371:58-66. doi:10.1016/j.tox.2016.10.001
6. Hanigan MH, Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. *Cancer Ther*. 2003;1:47-61.
7. Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-term renal outcomes after cisplatin treatment. *Clin J Am Soc Nephrol*. 2016;11(7):1173-1179. doi:10.2215/CJN.08070715
8. McSweeney KR, Gadanec LK, Qaradakh T, Ali BA, Zulli A, Apostolopoulos V. Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations. *Cancers (Basel)*. 2021;13(7):1572. doi:10.3390/cancers13071572
9. Milne B, Gilbey T, De Somer F, Kunst G. Adverse renal effects associated with cardiopulmonary bypass. *Perfusion*. 2023;39(3):452-468. doi:10.1177/02676591231157055
10. Oh GS, Kim HJ, Shen A, et al. Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. *Electrolyte Blood Press*. 2014;12(2):55-65. doi:10.5049/EBP.2014.12.2.55

11. Özdemir İ, Öztürk T, Amanvermez D, et al. The effects of perioperative goal-directed therapy on acute kidney injury after cardiac surgery in the early period. *Turk Gogus Kalp Damar Cerrahisi Derg.* 2023;31(4):467-478. doi:10.5606/tgkdc.dergisi.2023.24987
12. Palomba H. Intraoperative fluid balance and cardiac surgery-associated acute kidney injury: a multicenter prospective study. *Braz J Anesthesiol.* 2022;72(5):688-694. doi:10.1016/j.bjane.2022.07.006
13. Yang P, Yang T, Zhang J, et al. Enhancing cancer treatment through combined approaches: photodynamic therapy in concert with other modalities. *Pharmaceutics.* 2024;16(11):1420. doi:10.3390/pharmaceutics16111420
14. Roy N. Glutathione depletion and stalwart anticancer activity of metallothiopythetics inducing programmed cell death: opening a new window for cancer therapy. *ACS Omega.* 2024;9(19):20670-20701. doi:10.1021/acsomega.3c08890
15. Hu Y, Qin J, Ma Y, et al. Comprehensive review on the novel immunotherapy target: leucine-rich repeat-containing 8A/volume-regulated anion channel. *Int J Biol Sci.* 2024;20(10):3881-3891. doi:10.7150/ijbs.95933
16. Sørensen BH. Acquired cisplatin resistance in human ovarian A2780 cancer cells correlates with shift in taurine homeostasis and ability to volume regulate. *Am J Physiol Cell Physiol.* 2014;307(11):C1071-C1080. doi:10.1152/ajpcell.00274.2014
17. Widmer CA, Klebic I, Domanitskaya N, et al. Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacy. *Cancer Res Commun.* 2022;2(10):1266-1281. doi:10.1158/2767-9764.CRC-22-0208
18. Wilczyński B, Dąbrowska A, Saczko J, Kulbacka J. The role of chloride channels in the multi-drug resistance. *Membranes.* 2021;12(1):38. doi:10.3390/membranes12010038
19. Pilipovic A, Tepavcevic V, Kumar D, et al. Cyclodextrins, surfactants and their inclusion complexes. *Molecules.* 2025;30(19):3944. doi:10.3390/molecules30193944
20. Antoniou AI, Giofrè S, Seneci P, Passarella D, Pellegrino S. Stimulus-responsive liposomes for biomedical applications. *Drug Discov Today.* 2021;26(8):1794-1824. doi:10.1016/j.drudis.2021.05.010
21. Lee Y, Thompson DH. Stimuli-responsive liposomes for drug delivery. *WIREs Nanomed Nanobiotechnol.* 2017;9(5):e1450. doi:10.1002/wnan.1450
22. Wang J, Ayano E, Maitani Y, Kanazawa H. Tunable surface properties of temperature-responsive polymer-modified liposomes induce faster cellular uptake. *ACS Omega.* 2017;2(1):316-325. doi:10.1021/acsomega.6b00342
23. Motamarry A, Asemani D, Haemmerich D. Thermosensitive liposomes. In: *Liposomes*. InTech; 2017. doi:10.5772/intechopen.68159
24. Bi H, Xue J, Jiang H, et al. Current developments in drug delivery with thermosensitive liposomes. *Asian J Pharm Sci.* 2019;14(4):365-379. doi:10.1016/j.ajps.2018.07.006
25. Alrbyawi H. Stimuli-responsive liposomes of 5-fluorouracil: progressive steps for safe and effective treatment of colorectal cancer. *Pharmaceutics.* 2024;16(7):966. doi:10.3390/pharmaceutics16070966
26. Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand-targeted liposome design: challenges and fundamental considerations. *Trends Biotechnol.* 2014;32(1):32-45. doi:10.1016/j.tibtech.2013.09.007
27. Belfiore L, Saunders DN, Ranson M, Thurecht KJ, Storm G, Vine KL. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: challenges and opportunities. *J Control Release.* 2018;277:1-13. doi:10.1016/j.jconrel.2018.02.040
28. Romberg B, Hennink WE, Storm G. Sheddable coatings for long-circulating nanoparticles. *Pharm Res.* 2008;25(1):55-71. doi:10.1007/s11095-007-9348-7
29. Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Optimizing design parameters of ligand-targeted liposomes for improved therapeutic efficacy. *ACS Nano.* 2013;7(4):2935-2947. doi:10.1021/nn305631n
30. Chen S, Jiang S. A new class of zwitterionic polymeric liposomes. *Langmuir.* 2011;27(1):1-5. doi:10.1021/la103132e

31. Abu Lila AS, Ishida T. Accelerated blood clearance (ABC) phenomenon: clinical relevance and strategies to overcome. *Pharmaceutics*. 2020;12(12):1158. doi:10.3390/pharmaceutics12121158
32. Miller RP, Tadagavadi RK, Ramesh G. Mechanisms of cisplatin nephrotoxicity. *Toxins*. 2010;2(11):2490-2518. doi:10.3390/toxins2112490
33. Gong J, et al. Emerging chemotherapy agents in lung cancer: nanoparticle therapeutics for non-small cell lung cancer. *Transl Cancer Res*. 2015;4(4):340-355. doi:10.3978/j.issn.2218-676X.2015.08.01
34. Plummer R, Wilson RH, Calvert H, et al. A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. *Br J Cancer*. 2011;104(4):593-598. doi:10.1038/bjc.2011.6
35. Zhang P, Sun F, Tsao C, et al. Zwitterionic gel-encapsulated isogenic islet-cell grafts in mice and a fatty-tissue-ablated non-human primate model. *Nat Biotechnol*. 2021;39(7):812-818.
36. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: design and applications of PEG-drug conjugates and surface-modified nanoparticles. *Angew Chem Int Ed Engl*. 2010;49(36):6288-6308.
37. Gandhi S, Shende P. Cyclodextrins-modified metallic nanoparticles for effective cancer therapy. *J Control Release*. 2021;339:41-50. doi:10.1016/j.jconrel.2021.09.025
38. Zheng J, Sun Y, Shen Y, et al. Surface engineering of nanoparticles for precision medicine. *Precis Med Eng*. 2025;2(3):100037. doi:10.1016/j.preme.2025.100037
39. Zhao CC, Ye Y, Li ZQ, Wu XH, et al. Effect of goal-directed fluid therapy on renal function in critically ill patients: a systematic review and meta-analysis. *Ren Fail*. 2022;44(1):777-789. doi:10.1080/0886022X.2022.2072338
40. Uchino H, Matsumura Y, Negishi T, et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. *Br J Cancer*. 2005;93(6):678-687. doi:10.1038/sj.bjc.6602772
41. Han Y, Yin W, Li J, et al. Intracellular glutathione-depleting polymeric micelles for cisplatin pro-drug delivery to overcome cisplatin resistance of cancers. *J Control Release*. 2018;273:30-39. doi:10.1016/j.jconrel.2018.01.019
42. Subbiah V, Grilley-Olson JE, Combest AJ, et al. Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine in patients with advanced solid tumors. *Clin Cancer Res*. 2018;24(1):43-51. doi:10.1158/1078-0432.CCR-17-1114
43. Osada A. NC-6004, a novel cisplatin nanoparticle, in combination with pembrolizumab for head and neck cancer. *Integr Clin Med*. 2019;3(2). doi:10.15761/ICM.1000147
44. Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: molecular mechanisms of action. *Eur J Pharmacol*. 2014;740:364-378. doi:10.1016/j.ejphar.2014.07.025
45. Zhou J, Kang Y, Chen L, et al. The drug-resistance mechanisms of five platinum-based antitumor agents. *Front Pharmacol*. 2020;11:583947. doi:10.3389/fphar.2020.583947
46. Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. *AAPS J*. 2012;14(2):303-315. doi:10.1208/s12248-012-9330-0
47. Jang Y, Jang J, Son J, Lee HY, Cho J. Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer. *Int J Pharm X*. 2026;11:100483. doi:10.1016/j.ijpx.2025.100483
48. Montizaan D, Yang K, Reker-Smit C, Salvati A. Comparison of the uptake mechanisms of zwitterionic and negatively charged liposomes by HeLa cells. *Nanomedicine*. 2020;30:102300. doi:10.1016/j.nano.2020.102300